Industry News

The Valens Company Reports Financial Results for the Fourth Quarter and Fiscal Year Ended November 30, 2020

Kelowna, B.C., February 24, 2021 – The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to report its fourth quarter and fiscal year financial results for the period ended November 30, 2020. “In fiscal year 2020, we transformed Valens from a leading…

Read more

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021 DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The…

Read more

Aurora and MedReleaf Australia announce strategic agreement

Aurora Cannabis announced it has entered into a strategic agreement with MedReleaf Australia. The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in Australia of Aurora’s MedReleaf, CanniMed and Aurora brands. Products covered by the agreement will be EUGMP certified and include dried flower, oils, and…

Read more

Valens closes previously announced bought deal financing

The Valens Company closed its previously announced bought deal public offering of units of the Company for total gross proceeds of $39.7mm. The Company sold 19.4mm Units at a price of $2.05/unit, including 2.3mm units sold pursuant to the exercise of the underwriters’ over-allotment option. The Company plans to use $32.0mm of the net proceeds…

Read more